For ventricular tachycardia (VT), catheter ablation is often seen as an option of last resort, however, some are questioning whether there has been too much emphasis on antiarrhythmic medication. In ...

Baltimore, MD - A report published this week has shown a high rate of ventricular tachycardia (VT) recurrence—as high as 75% at 14 months—in arrhythmogenic right ventricular dysplasia/cardiomyopathy ...

The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular ...

Six-month outcomes from the Ventricular Catheter Ablation Study, the first-in-human evaluation of its FieldForce Ablation System for ventricular tachycardia (VT), have been published in Circulation.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical ®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an ...

"FULCRUM-VT represents a seminal step forward in advancing ventricular tachycardia management by delivering positive, clinically meaningful results from the first large-scale, rigorously executed ...

Directing patients selectively to centers performing higher volumes of ventricular tachycardia (VT) ablation may help reduce in-hospital complications following the procedure, an observational study ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ...